Effects of age, race, and gender on the pharmacokinetics and pharmacodynamics of alogliptin, a novel and highly selective dipeptidyl peptidase-4 inhibitor, in healthy subjects.

被引：0
|
作者：
Karim, A. [1 ]
Fleck, P. [1 ]
Harrell, R. E., Jr. [2 ]
Harris, S. [3 ]
Keeter, K. [1 ]
Zhang, W. [1 ]
Mekki, Q. [1 ]
机构：
[1] Taked Global Res & Dev Ctr Inc, Deerfield, IL USA
[2] Arkansas Res med Testing LLC, Little Rock, AR USA
[3] SeaView Res Inc, Miami, FL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2008年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [1] Lack of effect of cyclosporine on the singledose pharmacokinetics of alogliptin, a novel dipeptidyl peptidase-4 inhibitor, in healthy male subjects.
    Karim, A.
    Chiselko, P.
    Fleck, P.
    Harris, S.
    Munsaka, M.
    Mekki, Q.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S13 - S13
  • [2] Assessment of drug interaction between alogliptin, a highly selective dipeptidyl peptidase-4 inhibitor, and atorvastatin in healthy subjects.
    Karim, A.
    Fleck, P.
    Harris, S.
    Munsaka, M.
    Weiss, M.
    Mekki, Q.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S14 - S14
  • [3] Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
    Christopher, Ronald
    Covington, Paul
    Davenport, Michael
    Fleck, Penny
    Mekki, Qais A.
    Wann, Elisabeth R.
    Karim, Aziz
    CLINICAL THERAPEUTICS, 2008, 30 (03) : 513 - 527
  • [4] Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects
    Upreti, Vijay V.
    Boulton, David W.
    Li, Li
    Ching, Agatha
    Su, Hong
    LaCreta, Frank P.
    Patel, Chirag G.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (01) : 92 - 102
  • [5] Lack of dermal toxicity with the highly selective dipeptidyl peptidase-4 inhibitor alogliptin in monkeys
    Sato, Keiichiro
    Ozaki, Harushige
    Salamon, Clare M.
    Christopher, Ronald J.
    Yamamoto, Masaki
    DIABETES, 2008, 57 : A580 - A580
  • [6] Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment
    Karim, Aziz
    Fleck, Penny
    Hetman, Laura
    Marbury, Thomas
    Ravis, William R.
    Cannon, Courtney
    Zhang, Wen-Can
    Mekki, Qais
    DIABETES, 2008, 57 : A160 - A160
  • [7] Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor
    Boulton, David W.
    CLINICAL PHARMACOKINETICS, 2017, 56 (01) : 11 - 24
  • [8] Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor
    David W. Boulton
    Clinical Pharmacokinetics, 2017, 56 : 11 - 24
  • [9] Single-Dose Pharmacokinetics and Pharmacodynamics of Sitagliptin, an Inhibitor of Dipeptidyl Peptidase-4, in Healthy Indian Male Subjects
    Sangle, Ganesh V.
    Patil, Mohan
    Deshmukh, Nitin
    Kamble, Shantibhushan
    Vuppalavanchu, Kiran Kumar
    Kale, Sushil
    Baig, Layeeq
    Singh, Geetchandra
    Shaikh, Javed
    Tripathi, Jitendra
    Aravindababu, P.
    DIABETES, 2017, 66 : A630 - A630
  • [10] Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
    Pratley, Richard E.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (03) : 503 - 512
12345